Katina Dorton

Ms. Dorton has served on the board of directors since March 2021. She currently serves as Chief Financial Officer of Nodthera, a company developing medicines to inhibit the NLRP3 inflammasome. She also serves on the board of directors for Fulcrum Therapeutics (Nasdaq: FULC) and US Ecology (Nasdaq: ECOL) and previously served on the Board of Pandion Therapeutics ( Nasdaq: PAND) until its acquisition by Merck in 2021. Previously Ms. Dorton has held CFO positions at several biotechnology companies, including Repare Therapeutics, synthetic lethality, and DNA repair-focused oncology company, AVROBIO, a lentiviral gene therapy company, and Immatics GmbH. Earlier in her career, Ms. Dorton served as a Managing Director in investment banking for Morgan Stanley and Needham & Company and as an attorney at Sullivan & Cromwell. Ms. Dorton received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University, and her B.A. from Duke University.